期刊文献+

新诊断2型糖尿病患者血糖水平及用药特点316例分析 被引量:5

下载PDF
导出
摘要 目的回顾性分析316例新诊断2型糖尿病患者的血糖水平及用药特点。方法以316例新诊断2型糖尿病患者为研究对象,分析其空腹血糖、糖化血红蛋白水平,并总结其治疗方案特点。结果 316例新诊断2型糖尿病患者平均糖化血红蛋白为(8.4±1.5)%。目前应用较广泛的降糖药物依次为:糖苷酶抑制剂(44.2%)、磺脲类(35.5%)、二甲双胍(33.8%)、格列奈类(23.3%)、胰岛素(16.4%)。2种及以上口服药联合治疗率为50.3%。结论新诊断2型糖尿病患者基线血糖水平较高,口服降糖药治疗是应用最为广泛的降糖治疗方案。
出处 《中国临床医生杂志》 2011年第9期26-28,共3页 Chinese Journal For Clinicians
  • 相关文献

参考文献6

二级参考文献27

  • 1陆小平,王闻博,晏玲,龚雄辉,崔岚,刘悦,张小苏,李秀梅,王鸿玉.吸烟对男性2型糖尿病患者血糖控制的影响[J].中华内分泌代谢杂志,2003,19(4):294-295. 被引量:28
  • 2张家庆.血糖及其他体液葡萄糖测定进展[J].中华内分泌代谢杂志,2003,19(4):333-335. 被引量:59
  • 3[19]Spengler M,Hobler H,Cagatay M.Long-term tolerability of acarbose.In:Lefèbvre PJ,Standl E,editors.New aspects in diabetes.Treatment strategies with alpha-glucosidase inhibitors[J].De Gruyter,Berlin,1992,286.
  • 4[20]Hollander PA.Safety profile of acarbose,an alpha glucosidase inhibitor[J].Drugs,1993,44(Suppl 2):47.
  • 5[21]Gentile S,Turco S,Guarino G,et al.Aminotransferase activity and acarbose treatment in patients with type-2 diabetes[J].Diabetes Care,1999,22(7):1217.
  • 6[22]Kono T,Hayami M.Acarbose-induced generalized erythema multiforme[J].Lancet,1999,354:396.
  • 7[1]Cockram CS.The epidemiology of diabetes mellitus in the Asiapacific region[J].HKMJ,2000,6(1):43.
  • 8[2]Lebowitz HE.α-Glucosidase inhibitors as agents in the treatment of diabetes[J].Diabetes Review,1998,6(2):132.
  • 9[3]Hoffmann J,Spengler M.Efficacy of 24-week monotherapy with acarbose,metformin or placebo in dietary-treated NIDDM patients:The Essen-Ⅱ Study[J].Am J Med,1997,103:483.
  • 10[4]Hoffmann J,Spengler M.The Essen I Study:efficacy of 24 week monotherapy with acarbose,glibenclamide or placebo in NIDDM patients[J].Diabetes Care,1994,17(6):561.

共引文献223

同被引文献45

  • 1范泉,郭文怡,贾国良.冠心病患者糖化血红蛋白水平与冠状动脉病变的相关性[J].第四军医大学学报,2006,27(8):698-700. 被引量:76
  • 2Bartnik M, Malmberg K, Norhammar A, et al. Newly detected abnormalglucose tolerance : an important predictor of long term outcome after myocardial infarction [J]. Eur Heart J, 2004, 25 (22) : 1990-1997.
  • 3Tanaka T, Nakamura Y, Nasuno A, et al. Plasma concentrations of monocyte TC emoattractant protein 1 ( MCP-1 ) and neopterin in the coronary circulation of patients with coronary artery disease [ J]. CircJ,2004,68 (02) : 114-120.
  • 4Ina N,Zdenka T, Lea D, et al. Humoral methylglyoxal levelreflects glycemic fluctuation [ J J. Clin Biochem, 2005, 38 (04) : 379-383.
  • 5Slevin E, Marinopoulos, berkenbilit G, et al. Meta-analysis: Glycoylated hemoglobin and cardiovascular disease in diabetes mellitus[ J]. Ann Inter Med,2004,2: 141.
  • 6Kalousova M, Zima T, Tesat V, et al. Advanced rlycation end products and advanced oxidation protein products in hemodialyzed patients[ J]. Blood Purif,2002,20: 531-536.
  • 7Clee man J I.Excutive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation , and treatment of high blood cholesterol in adults[J].JAMA, 2001, 285 ( 19 ) : 2468-2497.
  • 8Colhoun H M, Betteridge D J, Durrington P N, et al.Primary prevention of cardiovascular disease with atorvastain in type 2 diabetes in the Collaborative Atorvastain Diabetes Study( CARDS ) : Multicentre randomised placebo-controlled trial[J]. Lancet, 2004, 364 ( 9345 ) : 685-696.
  • 9Bartnik M, MalmbergK, Norhammar A, et al.Newly detected abnormal glucose tolerance: animportant predictor of long-term outcome after myocardial infarction[J].Eur Heart J,2004, 25 ( 22 ): 1990-1997.
  • 10American Diabetes Association.Standard of medical care in diabetes[J].Diabetes Care, 2007, 30 ( 5 ) : 40-41.

引证文献5

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部